Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas
Tóm tắt
This Phase I study was designed to build on the Gastrointestinal Tumor Study Group’s experience with combined modality therapy in patients with pancreatic cancer. Thirteen patients with adenocarcinoma of the pancreas received weekly 5-fluorouracil by rapid intravenous infusion midway through a 2-h infusion of high dose leucovorin during external beam radiation therapy. Twelve patients received 100% of planned external beam radiation; treatment delays occurred in only three. Four patients received 100% of planned chemotherapy doses. Leukopenia and thrombocytopenia caused reduction of the number of chemotherapy doses given during radiation in six patients; diarrhea, severe nausea and vomiting, and wound abscess caused reduction in three patients. Ten patients were evaluable for response; two had complete responses, one had a partial response, and two had minor responses. In this small series baseline and post-treatment CA 19-9 levels predicted and correlated with response. We conclude that radiation and 5-FU modulated by leucovorin is a tolerable treatment regimen for carcinoma of the pancreas, with preliminary suggestion of activity, that warrants further Phase II testing.
Tài liệu tham khảo
Boring CC, Squires TS, Tong T. Cancer statistics. CA 1991 ; 41: 18–37.
Menck HR, Garfinkel L, Dodd GD. Preliminary report of the national cancer data base. CA 1991; 41: 7–19.
Kaiser MH, Ellenberg SS. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection.Arch Surg 1985; 120: 899–903.
Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer.Cancer 1987; 59: 2006–2010.
Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kaiser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads) + 5-fluorouracil, and high dose radiation + 5-fluorouracil.Cancer 1981; 48: 1705–1710.
Bruso CE, Shewach DS, Lawrence TS. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells.Int J Radiat Oncol Biol Phys 1991; 19: 1411–1417.
Moran RG. Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate.Cancer 1989; 63: 1008–1012.
Grinblatt DL, Benson AB, III. Response of pancreatic carcinoma to 5-fluorouracil and leucovorin.Am J Med 1992; 92: 107–109.
Bruckner HW, Crown J, Mckenna A, Hart R. Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors.Cancer Res 1988; 48: 5570–5572.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment.Cancer 1981; 47: 207–214.
Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H, Pugliese V. CA19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.Cancer 1988; 61: 2100–2108.